Asian Pacific Journal of Cancer Prevention

아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Cytotoxicity Effects of Mouse IgG Produced against Three Nanoliposomal Human DR5 Receptor Epitopes on Breast Cancer Cells

  • Amirijavid, Shaghayegh (Department of Genetics, Tehran Medical Sciences Branch, Islamic Azad University) ;
  • Entezari, Maliheh (Department of Genetics, Tehran Medical Sciences Branch, Islamic Azad University) ;
  • Movafagh, Abolfazl (Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences) ;
  • Hashemi, Mehrdad (Department of Genetics, Tehran Medical Sciences Branch, Islamic Azad University) ;
  • Mosavi-Jarahi, Alireza (Department of Epidemiology, School of Medicine, Shahid Beheshti University of Medical Sciences) ;
  • Dehghani, Hossein (Department of Medical laboratory Sciences, Tehran Medical Sciences Branch, Islamic Azad University)
  • 발행 : 2016.06.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Cancer causes cells to avoid death while being the second cause of death in the world itself. Damaged cells in the absence of apoptosis will increasingly amplify their inefficient genome. Of the two main apoptosis inducing pathways in cells, the first has p53 protein as the main initiating factor in the cascade. According to research results this protein s mutated in 50% of cancers and sointerest has cooncentrated on the second pathway that features death receptors. Among these receptors TRAIL1/DR5 is especially expressed in cancer cells. So targeting such receptors can initiate the apoptotic cascade in cells. Interestingly by substitution of activating ligands with antibodies as agonists, we could efficiently turn on the apoptosis pathway. First of all, three small peptides from the DR5 protein extracellular domain were synthesized and injected with two different kind of adjuvants (Fround and liposomal encapsulation) separately into mice at 15 day intervals. As a result, liposomal peptides induced the immune system more efficient than Frounds adjuvant and at the end point the antibodies which were obtained from liposomal peptide injection induced much more effective death. Liposomal formol could be used as an adjuvant in immunization utilizing small peptides. They carry, protect and deliver peptides very efficiently. In addition, small peptides of a certain size from the extracellular domain of DR5 proteins not only can induce immune system but also produce antibodies playing a remarkable anti-cancer roles against breast cancer cells (MCF-7).

키워드

참고문헌

  1. Almasan A, Ashkenazi A (2003). Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev, 14, 337-48. https://doi.org/10.1016/S1359-6101(03)00029-7
  2. Amirijavid S, Hashemi M (2015). Detection of anticancer and apoptotic effect of the produced IgYs against the three extracellular domain of human DR5 protein. Iran J Cancer Prev, 8,109-15.
  3. Amirijavid S, Hashemi M (2014). Anticancer effect of the IgY that produced against a small peptide with 15 amino acids of human DR5 on MCF7 cell line. JPS, 5,1-6.
  4. Ashkenazi A (2002). Targeting death and decoy receptors of the tumor necrosis factor superfamilly. Nat Rev Cancer, 2, 420-300. https://doi.org/10.1038/nrc821
  5. Bellail AC, Qi L, Mulligan P, et al (2009). TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev Recent Clin Trials, 4, 34-41. https://doi.org/10.2174/157488709787047530
  6. Benedict CA, Banks TA, et al. (2003). Death and survivel: viral regulation of TNF signaling pathways.Curr Opin Immunol, 15, 59-65. https://doi.org/10.1016/S0952-7915(02)00018-3
  7. Bodmer JL, Schneider P, et al (2002). The molecular architecture of the TNF superfam.Trends. Biochem Sci, 27,19-26. https://doi.org/10.1016/S0968-0004(01)01995-8
  8. Cha SS, Sung BJ, et al. (2000). Crystal structure of TRAIL-DR5 complex identifies a critical role of the unique frame insertion in conferring recognition specificity. J BiolChem, 275, 31171-7.
  9. Chaudhary PM, Eby M, et al (1997). Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappa B pathway. Immunity,7,821-30. https://doi.org/10.1016/S1074-7613(00)80400-8
  10. Heidari MH, Porghasem M, Mirzaei N, et al (2014). The effect of high level natural ionizing radiation on expression of PSA, CA19-9 and CEA tumor markers in blood serum of inhabitants of Ramsar, Iran. J Environ Radioact, 128, 64-7. https://doi.org/10.1016/j.jenvrad.2013.11.001
  11. Gajewski TF (2007). On the TRAIL toward death receptor-based cancer therapeutics. J Clin Oncol, 25,1305-7. https://doi.org/10.1200/JCO.2006.09.9804
  12. Ichikawa K, Liu W, et al (2001). Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med,7, 954-60. https://doi.org/10.1038/91000
  13. Kelley RF, Totpal K, et al (2005). Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J BiolChem, 280, 2205-12.
  14. Mahalingam D, Szegezdi E, et al (2009). TRAIL receptor signalling and modulation: Are we on the right TRAIL?. Cancer Treat Rev, 35, 280-8. https://doi.org/10.1016/j.ctrv.2008.11.006
  15. Mori E, Thomas M, et al (2004). Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2. Cell Death Differ, 11, 203-7. https://doi.org/10.1038/sj.cdd.4401331
  16. Movafagh A, Hajifathali A, Zamani M (2011). Secondary chromosomal abnormalities of de novo acute myeloid leukemia-a first report from the Middle East. Asian Pac J Cancer Prev, 12, 2991-4.
  17. Movafagh A, Mirfakhraei R, Mousavi-Jarrahi A (2011). Frequent incidence of double minute chromosomes in cancers, with special up-to-date reference to leukemia. Asian Pac J Cancer Prev, 12, 3453-6.
  18. Movafagh A, Hajifathali A, Isfahani F, et al (2012). Geographic heterogeneity of cytogenetic characteristics of acute myeloid leukemia in the early detection. Iran J Cancer Prev, 2, 85-89.
  19. Pan G, Ni J, et al (1997). Anantagonist decoyreceptor and a death domain-containing receptor for TRAIL. Science , 277,815-8. https://doi.org/10.1126/science.277.5327.815
  20. Pan G, O'Rourke K, et al (1997). The receptor for the cytotoxic ligand Trail. Science , 276,111-3. https://doi.org/10.1126/science.276.5309.111
  21. Peto R, Boreham J, et al (2000). UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet, 355, 1822-3.
  22. Reed JC (2006). Drug insight cacner therapy strategis, based on restoration of endogenous cell death mechanism. Nat clin pract oncol, 3, 388-98. https://doi.org/10.1038/ncponc0538
  23. Schneider P, Thome M, et al (1997). TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity,7, 831-6. https://doi.org/10.1016/S1074-7613(00)80401-X
  24. Seifi-Alan M, Shamsi R, Ghafouri-Fard S, et al (2014). Expression analysis of two cancer-testis genes, FBXO39 and TDRD4, in breast cancer tissues and cell lines. Asian Pac J Cancer Prev, 14, 6625-9.
  25. Shargh SA, Sakizli M, Khalaj V, et al ( 2014) Downregulation of E-cadherin expression in breast cancer by promoter hypermethylation and its relation with progression and prognosis of tumor. Med Oncol, 31, 250-9. https://doi.org/10.1007/s12032-014-0250-y
  26. Walczak H, Degli-Esposti MA, et al (1997). Trail R2: a novel apoptosis mediating receptor. EMBO,16, 5386-97. https://doi.org/10.1093/emboj/16.17.5386
  27. Wei W, Liu Y, et al (2005). Current understanding on the immunological functions of tumor necrosis factor-related apoptosis-inducing ligand. Cell MolImmunol, 2, 265-9.
  28. Wiley SR, Schooley K, et al (1995). Identification and characterization of a new member of theTNF family that induces apoptosis. Immunity, 3, 673-82. https://doi.org/10.1016/1074-7613(95)90057-8
  29. Wu GS, Burns TF, et al (1997). KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nature Genet, 17, 141-3. https://doi.org/10.1038/ng1097-141